Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

prevention and screening

(2008)   ANNALS OF ONCOLOGY

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

(2008) M S Kim et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines

(2008) L. M. Laguinge et al.   CANCER RESEARCH

Mcl-1: A Gateway to TRAIL Sensitization

(2008) S.-H. Kim et al.   CANCER RESEARCH

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Making progress against cancer in Europe in 2008

(2008) Tit Albreht et al.   EUROPEAN JOURNAL OF CANCER

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

(2008) Anne Grosse-Wilde et al.   JOURNAL OF CLINICAL INVESTIGATION

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

(2008) Niklas Finnberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY